150 Mg Trastuzumab Lyophilized Powder For Concentrate For Solution For Infusion

Name: 150 Mg Trastuzumab Lyophilized Powder For Concentrate For Solution For Infusion
Brand: NEETCO BIOPHARMA
Price: 8000 INR
Availability: InStock

Price 8000 INR/ Vial

Get a Price/Quote

MOQ : 10 Vials

150 Mg Trastuzumab Lyophilized Powder For Concentrate For Solution For Infusion Specification

Dosage Form
Lyophilized Powder for Concentrate for Solution for Infusion

Salt Composition
Trastuzumab 150 mg per vial

Indication
Treatment of HER2-positive breast cancer and metastatic gastric cancer

Enzyme Types
Not applicable (Monoclonal antibody, not enzyme)

Feature
High specificity for HER2 receptor, stable formulation, suitable for targeted cancer therapy.

Ingredients

Application
Intravenous infusion after reconstitution and dilution

Ph Level
Approximately 6.0 after reconstitution

Temperature Needed For Fermentation
Not applicable (Product manufactured via cell culture in bioprocess, specific proprietary information)

Physical Color/Texture
Off-white to pale yellow lyophilized powder

Fermentation Smell
Odorless (no distinctive fermentation smell)

Enzymatic Activity
Not applicable (monoclonal antibody)

Storage Instructions
Store unopened vial at 2°C to 8°C in refrigerator. Do not freeze.

Shelf Life
24 months from manufacturing date under recommended storage conditions.

Compatibility
Compatible only with sodium chloride 0.9% solution; do not use with glucose solutions

Packaging
Carton box containing vial, package insert and traceability label

Barcodes/Traceability
Unique barcode and lot number for hospital traceability

Dilution Instructions
Further dilute required dose in infusion bag containing sodium chloride 0.9% solution

Route of Administration
Intravenous infusion

Prescription Status
Prescription-only medicine (Rx)

Visual Inspection
Inspect after reconstitution for particulate matter and discoloration before administration

Precautions
Monitor for infusion-related reactions, cardiotoxicity, and pulmonary events during therapy

Contraindications
Hypersensitivity to trastuzumab or any excipient

Reconstitution
Reconstitute with 7.2 mL sterile water for injection to yield a 21 mg/mL solution

Therapeutic Class
Antineoplastic pharmacologic agent (HER2 inhibitor)

Infusion Time
Initial dose infused over 90 minutes, subsequent doses over 30 minutes

Container Type
Single use glass vial with rubber stopper

Strength
150 mg/vial

Market Authorization
Regulated by national health authorities (e.g., FDA, EMA, DCGI)

About 150 Mg Trastuzumab Lyophilized Powder For Concentrate For Solution For Infusion

Highlighted as an elite option in targeted oncologic therapy, 150 mg Trastuzumab Lyophilized Powder for Concentrate for Solution for Infusion presents patients and clinicians with an astonishingly effective HER2 inhibitor. This prescription-only antineoplastic agent is noteworthy for its sublime specificity to the HER2 receptor, rendering it an ideal choice for HER2-positive breast and metastatic gastric cancers. Packaged securely in a single-use glass vial, the product requires careful reconstitution and dilution strictly with sodium chloride 0.9%. Its meticulously regulated formulation ensures a high standard of safety and clinical reliability-truly a bargain for trusted advanced oncologic care.

Application Areas and Key Features

150 mg Trastuzumab is widely used for the treatment of HER2-positive breast cancer and metastatic gastric cancer. This sublime formulation offers high specificity, ensuring targeted therapy and minimizing side effects. Key features include its stable lyophilized powder form, off-white to pale yellow color, compatible exclusively with sodium chloride 0.9%, and secure single-use vial packaging. Its efficacy in advanced oncology makes it a noteworthy solution for elite cancer care programs and hospital infusion centers.

Sample Availability, Market Coverage, and Secure Delivery

Samples of 150 mg Trastuzumab are available upon request, allowing healthcare institutions to evaluate this top-tier therapy. Our supply network covers the main domestic market in India, and we offer proposal amounts tailored to individual clinical requirements. With secure shipping and barcoding for traceability, delivery times are short and dependable, further highlighting our commitment to timely, safe, and regulated provision of this vital antineoplastic agent.

FAQ's of 150 Mg Trastuzumab Lyophilized Powder For Concentrate For Solution For Infusion:

Q: How is 150 mg Trastuzumab Lyophilized Powder prepared for infusion?

A: Reconstitute the powder with 7.2 mL sterile water for injection, yielding a 21 mg/mL solution. The required dose should be further diluted in an infusion bag with sodium chloride 0.9% solution before intravenous infusion.

Q: What conditions is this product used to treat?

A: 150 mg Trastuzumab is used primarily for the treatment of HER2-positive breast cancer and metastatic gastric cancer, offering targeted therapeutic benefit through HER2 inhibition.

Q: When should Trastuzumab not be administered?

A: This product is contraindicated in patients with hypersensitivity to trastuzumab or any excipient in its composition. It should not be used with glucose solutions.

Q: Where should the unopened vial be stored for optimal stability?

A: Store the unopened vial in a refrigerator at 2C to 8C. Do not freeze the product to maintain its potency and shelf life.

Q: What are key precautions during therapy with Trastuzumab?

A: Patients should be carefully monitored for infusion-related reactions, cardiotoxicity, and pulmonary events throughout therapy. Visual inspection after reconstitution is also essential to ensure solution clarity before administration.

Q: How does the traceability system benefit hospital usage?

A: A unique barcode and lot number on each package ensure hospital traceability, facilitating reliable inventory management and product safety monitoring.

Tell us about your requirement